Cargando…

Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid

Whereas significant strides have been made in the treatment of lysosomal storage diseases (LSDs), the neuronopathy associated with these diseases remains impervious mainly because of the blood-brain barrier (BBB), which prevents delivery of large molecules to the brain. However, 100 years of researc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Yuji, Minami, Kohtaro, Hirato, Toru, Tanizawa, Kazunori, Sonoda, Hiroyuki, Schmidt, Mathias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283362/ https://www.ncbi.nlm.nih.gov/pubmed/35088290 http://dx.doi.org/10.1007/s11011-021-00893-3

Ejemplares similares

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
por: Sonoda, Hiroyuki, et al.
Publicado: (2022)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases
por: Jakóbkiewicz-Banecka, Joanna, et al.
Publicado: (2013)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
por: Flunkert, Stefanie, et al.
Publicado: (2022)

Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease
por: Zigdon, Hila, et al.
Publicado: (2015)

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
por: Yamamoto, Ryuji, et al.
Publicado: (2021)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients
por: Bhalla, Akhil, et al.
Publicado: (2020)

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
por: Okuyama, Torayuki, et al.
Publicado: (2019)

Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme
por: Hahn, Andreas, et al.
Publicado: (2022)

The rapidly evolving view of lysosomal storage diseases
por: Parenti, Giancarlo, et al.
Publicado: (2021)

Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice
por: Morimoto, Hideto, et al.
Publicado: (2022)

Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses
por: Minami, Kohtaro, et al.
Publicado: (2022)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities
por: Suzuki, Yoshiyuki, et al.
Publicado: (2009)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease
por: Sergijenko, Ana, et al.
Publicado: (2013)

Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice
por: Imakiire, Atsushi, et al.
Publicado: (2023)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Grant, Nathan
Publicado: (2020)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
por: de Castro, María José, et al.
Publicado: (2021)

Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease
por: Srikanth, Manasa P., et al.
Publicado: (2020)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid
por: Boman, Andrea, et al.
Publicado: (2016)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Macrophages in Giemsa-stained cerebrospinal fluid specimens predict carcinomatous meningitis
por: Kobayashi, Sayaka, et al.
Publicado: (2020)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Correction: Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
Publicado: (2014)

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil
por: Giugliani, Roberto, et al.
Publicado: (2021)

Lysosomes and Lysosomal Storage Diseases
por: Noebels, Jeffrey L.
Publicado: (1981)

Blood Cerebrospinal Fluid Barrier Function Disturbance Can Be Followed by Amyloid-β Accumulation
por: Suzuki, Yuji, et al.
Publicado: (2022)

Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice
por: Morimoto, Hideto, et al.
Publicado: (2021)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
por: Tomita, Kazuyoshi, et al.
Publicado: (2021)

Embryonic blood-cerebrospinal fluid barrier formation and function
por: Bueno, David, et al.
Publicado: (2014)

Choroid plexus and the blood–cerebrospinal fluid barrier in disease
por: Solár, Peter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q0arqddob48v6lau9h4a9i60vt